These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23304802)

  • 1. Cytogenetics helps determine diagnosis and prognosis for multiple myeloma.
    Becze E
    ONS Connect; 2012 Dec; 27(12):18-9. PubMed ID: 23304802
    [No Abstract]   [Full Text] [Related]  

  • 2. [Multiple myeloma: chromosomal abnormalities, clinical features and prognosis].
    Ishida T
    Rinsho Ketsueki; 2013 Oct; 54(10):1856-66. PubMed ID: 24064837
    [No Abstract]   [Full Text] [Related]  

  • 3. [Detection of complex chromosomal aberrations in patients with multiple myeloma using multiplex fluorescence in situ hybridization].
    Jiang YQ; Chen LJ; Zhu Y; Qiu HR; Wang R; Xu JR; Lu H; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Aug; 27(4):441-4. PubMed ID: 20677154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The significance and current diagnostic options of cytogenetic changes in multiple myeloma].
    Kuglík P; Filková H; Oltová A; Hájek R
    Vnitr Lek; 2006 Nov; 52 Suppl 2():76-8. PubMed ID: 18175433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interphase FISH for the detection of breakpoints in IG loci and chromosomal changes with adverse prognostic impact in multiple myeloma with normal karyotypes.
    Sáez B; Martín-Subero JI; Odero MD; Prosper F; Hernandez R; Cigudosa JC; Siebert R; Calasanz MJ
    Cancer Genet Cytogenet; 2006 Jun; 167(2):183-5. PubMed ID: 16737923
    [No Abstract]   [Full Text] [Related]  

  • 7. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Myeloma Genomics - A Concise Review.
    Castaneda O; Baz R
    Acta Med Acad; 2019 Apr; 48(1):57-67. PubMed ID: 31264433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chromosome abnormalities in multiple myeloma: personal experience and review of the literature].
    Rochon M; Cadotte M; Pretty HM; Long LA
    Union Med Can; 1971 Sep; 100(9):1750-4. PubMed ID: 5112012
    [No Abstract]   [Full Text] [Related]  

  • 10. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
    Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
    Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic studies in multiple myeloma: a study of fourteen cases.
    Tassoni EM; Durant JR; Becker S; Kravitz B
    Cancer Res; 1967 Apr; 27(4):806-10. PubMed ID: 6025735
    [No Abstract]   [Full Text] [Related]  

  • 12. [Genetic and cytogenetic abnormalities of multiple myeloma].
    Hanamura I; Iida S
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():126-32. PubMed ID: 23133940
    [No Abstract]   [Full Text] [Related]  

  • 13. [Application of FICTION technique to the detection of genetic aberrations in multiple myeloma].
    Wang D; Huang L; Zhang H; Geng Z; Shang Z; Zhou JF; Li CR
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):226-30. PubMed ID: 21569703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of genomics on the management of myeloma.
    Corre J; Avet-Loiseau H
    J Natl Compr Canc Netw; 2011 Oct; 9(10):1200-6. PubMed ID: 21975916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional cytogenetics in myeloma.
    Campbell LJ
    Methods Mol Med; 2005; 113():37-47. PubMed ID: 15968093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do we need cytogenetics in the follow-up of multiple myeloma?
    Gay F; Goldschmidt H
    Br J Haematol; 2019 May; 185(3):399-401. PubMed ID: 30706441
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of cytogenetics in myeloma.
    Zhan F; Sawyer J; Tricot G
    Leukemia; 2006 Sep; 20(9):1484-6. PubMed ID: 16926848
    [No Abstract]   [Full Text] [Related]  

  • 18. Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study.
    Lange K; Gadzicki D; Schlegelberger B; Göhring G
    Leuk Res; 2010 Aug; 34(8):1002-6. PubMed ID: 20022374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndrome with isochromosome 5p and trisomy 8 after treatment of a multiple myeloma.
    Jimenez-Sousa MA; Ferro MT; Talavera M; Villalon C; Cabello P; Laraña J; Herrera P; Garcia Sagredo JM
    Cancer Genet Cytogenet; 2010 Dec; 203(2):345-7. PubMed ID: 21156257
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of biological variables to predict outcome in multiple myeloma.
    Davies FE; Jack AS; Morgan GJ
    Br J Haematol; 1997 Dec; 99(4):719-25. PubMed ID: 9432013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.